Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-URS Chemotherapy for UTUC
NCT06167057Recruiting
- Sponsor
- Carmel Medical Center
- Start
- Apr 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of mitomycin c and gemcitabine in upper tract urothelial carcinoma (UTUC) (2 arms), sponsored by Carmel Medical Center. Primary endpoint: 1 year Intravesical Recurrence Free Survival. Started Apr 2023; status: recruiting.
02
Drugs
mitomycin cgemcitabine
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT06167057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06167057.